← Back to Search

Monoclonal Antibodies

Monoclonal Antibody Therapy for Leukemia

Phase 1

Waitlist Available

Research Sponsored by Parker Hughes Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age: 80 and under

Renal: Creatinine no greater than 1.5 times ULN, Creatinine clearance or radioisotope GFR at least 70 mL/min

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will monoclonal antibody therapy to see if it can kill cancer cells without harming normal cells.

Who is the study for?

This trial is for patients under 80 with recurrent acute lymphoblastic leukemia or non-Hodgkin's lymphoma, who've had up to three prior chemo treatments and no CNS disease. They must have certain levels of CD19 antigen positive blasts and can't be pregnant or nursing. Those with serious uncontrolled conditions or active infections are excluded.Check my eligibility

What is being tested?

The study tests monoclonal antibody therapy's ability to target and kill cancer cells in patients with specific types of leukemia and lymphoma without harming normal cells. It's a Phase I trial, which means it’s the first step in testing this treatment in humans.See study design

What are the potential side effects?

While not specified here, monoclonal antibody therapy may cause side effects such as allergic reactions, fever, chills, weakness, headache, nausea, vomiting; more severe effects could include low blood pressure or lung problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 80 years old or younger.

Select...

My kidney function tests are within the required range.

Select...

I don't have trouble breathing at rest, can exercise, and my lung tests are within normal ranges.

Select...

My lymphoma is one of the specified types.

Select...

My cancer cells are mostly CD19 positive.

Select...

My B-cell lymphoma hasn't responded to up to 3 treatments or returned after a bone marrow transplant.

Select...

I do not have any brain or spinal cord diseases.

Select...

My B-cell acute lymphoblastic leukemia has relapsed after initial chemotherapy.

Select...

My liver tests are within the required range.

Select...

I can care for myself but may not be able to do active work.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 10Eligibility criteria met

Find a Location

Who is running the clinical trial?

Parker Hughes Cancer CenterLead Sponsor

Fatih M. Uckun, MDStudy ChairParker Hughes Cancer Center

Media Library

Monoclonal Antibody Therapy (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00004858 — Phase 1

Leukemia Clinical Trial 2023: Monoclonal Antibody Therapy Highlights & Side Effects. Trial Name: NCT00004858 — Phase 1

Monoclonal Antibody Therapy (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004858 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still vacancies available for enrolment in this research?

"This medical study, which was initially posted 3/1/2000 and last modified 9/19/2013, is not currently searching for participants. Nevertheless, there are 2888 other clinical trials still recruiting patients at this time."

Answered by AI